85317-52-8

Basic information

• Product Name: 4-NITRO-PHENYLALANINE METHYL ESTER
• Synonyms: 4-NITRO-PHENYLALANINE METHYL ESTER;Nitro phenylalanine methyl ester;methyl 2-amino-3-(4-nitrophenyl)propionate
• CAS NO: 85317-52-8
• Molecular Formula: C₁₀H₁₂N₂O₄
• Molecular Weight: 224.21
• Mol File: 85317-52-8.mol

Chemical Properties

• Boiling Point: 360 °C at 760 mmHg
• Flash Point: 171.5 °C
• Appearance: /
• Density: 1.283 g/cm³
• Vapor Pressure: 2.29E-05mmHg at 25°C
• Refractive Index: 1.564
• PKA: 6.45±0.33(Predicted)
• CAS DataBase Reference: 4-NITRO-PHENYLALANINE METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-NITRO-PHENYLALANINE METHYL ESTER(85317-52-8)
• EPA Substance Registry System: 4-NITRO-PHENYLALANINE METHYL ESTER(85317-52-8)

Safety Data

• Hazardous Substances Data: 85317-52-8(Hazardous Substances Data)

Usage

Uses

Used in Biochemical Research Studies:
4-NITRO-PHENYLALANINE METHYL ESTER is used as a precursor for the synthesis of peptides and proteins, enabling researchers to study their structure, function, and interactions with other molecules.
Used in Enzyme Kinetics Studies:
4-NITRO-PHENYLALANINE METHYL ESTER is used as a substrate or inhibitor in enzyme kinetics studies, helping researchers understand the mechanisms of enzymatic reactions and the factors affecting their rates.
Used in Drug and Pharmaceutical Development:
4-NITRO-PHENYLALANINE METHYL ESTER is used in the development of new drugs and pharmaceuticals, serving as a building block or a template for designing novel therapeutic agents.
Used in Structure-Activity Relationship Studies:
4-NITRO-PHENYLALANINE METHYL ESTER is used as a tool to investigate the relationship between the molecular structure of compounds and their biological activities, providing insights into the design of more effective and selective drugs.

InChI:InChI=1/C10H12N2O4/c1-16-10(13)9(11)6-7-2-4-8(5-3-7)12(14)15/h2-5,9H,6,11H2,1H3

Upstream product

• 67-56-1 methanol 
• 1991-83-9 4-nitrophenylalanine 
• 17193-40-7 (+)-Methyl 2-amino-3-(4-nitrophenyl)propionate hydrochloride 

Downstream Products

• 120330-86-1 methyl N-formyl-(4-nitro)phenylalaninate 
• 929217-80-1 2-(2-tert-butoxycarbonylamino-acetylamino)-3-(4-nitro-phenyl)-propionic acid methyl ester 
• 623146-90-7 methyl 2-[(2,6-dichlorobenzyl)amino]-3-(4-nitrophenyl)propanoate 
• 623144-14-9 methyl 2-[(2,6-dichlorobenzoyl)amino]-3-(4-nitrophenyl)propanoate 
• 160132-37-6 4-[2-(n-butylsulfonylamino)-2-(methoxy-carbonyl)-ethyl]-aniline 
• 220847-34-7 4-nitro-N-[(2,6-dimethylphenyl)carbonyl]-L-phenylalanine methyl ester 
• 89288-22-2 2-amino-3-(4-nitrophenyl)propan-1-ol 
• 1160845-66-8 methyl α-(4-nitrobenzyl)diazoacetate 
• 1005484-25-2 1-(4-nitrobenzyl)-2-(1,4,7-triazacyclononan-1-yl)ethylamine 
• 1353022-73-7 2-[(4-methylphenyl)sulfonamido]-3-(4-nitrophenyl)propanamide 
• 1353022-74-8 N-[1-amino-3-(4-nitrophenyl)propan-2-yl]-4-methylbenzene-1-sulfonamide 
• 1353022-72-6 N-(1-{4,7-bis[(4-methylphenyl)sulfonyl]-1,4,7-triazonan-1-yl}-3-(4-nitrophenyl)propan-2-yl)-4-methylbenzene-1-sulfonamide 
• 105359-56-6 2-amino-3-(4-nitrophenyl)propanamide 
• 605670-02-8 N¹-(3-amino-propyl)-3-(4-nitro-phenyl)-propane-1,2-diamine 

Relevant articles and documents

Ligand and metal complex

A ligand of Formula (I) is provided: wherein A4 represents a hydrogen atom, a nitro group, an amino group, a thiocyanato group, or —Z—Y, in which Z is a divalent linking group and Y is a group derived from a biocompatible molecule, with the proviso that when X is methylene, A4 cannot be a hydrogen atom or a nitro group. A metal complex having the ligand is also provided and is useful as a blood pool contrast agent or a targeting contrast agent.

2,6-Quinolinyl derivatives as potent VLA-4 antagonists

A new series of 2,6-quinolinyl derivatives was prepared leading to potent low nanomolar VLA-4/VCAM-1 antagonists.

Synthesis and evaluation of a novel samarium-153 bifunctional chelating agent for radioimmunotargeting applications

A new bifunctional chelating agent (BCA), 3-(4-isothiocyanatobenzyl) triethylenetetraaminehexaacetic acid (9), has been synthesized in fast and easy conditions. An improved synthesis of its position isomer 1-(4- isothiocyanatobenzyl)triethylenetetraaminehexaacetic acid (19) is also described. Stability in serum media of the two corresponding aminobenzyl derivatives-samarium-153 complexes, respectively, 3-(4-aminobenzyl) triethylenetetraaminehexaacetic acid-samarium-153 and 1-(4-aminobenzyl) triethylenetetraaminehexaacetic acid-samarium-153, have been evaluated. The 3-(4-aminobenzyl)triethylenetetraaminehexaacetic acid complex revealed excellent stability in serum media, and therefore 3-(4-isothiocyanatobenzyl) triethylenetetraaminehexaacetic acid (9) appears useful for future in vivo radioimmunotherapy investigations. Copyright

2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS

The present invention concerns 2,6-quinolinyl and 2,6-naphthyl derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for the treatment of VLA-4 dependent inflammatory diseases such as for example asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and atherosclerosis. Formula (I): wherein X is N or CH.

Biospecific binding reactants labelled with luminescent lanthanide chelates and their use

This invention relates to a detectable molecule comprising a biospecific binding reactant attached to a luminescent lanthanide chelate comprising a lanthanide ion and a chelating ligand of the formula STR1 wherein --A-- is a bivalent aromatic structure se

CARBOXYLIC ACID COMPOUND HAVING CONDENSED RING, SALT THEREOF AND PHARMACEUTICAL USE THEREOF

A novel carboxylic acid compound having a condensed ring, which is represented by the formula (I) wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and pharmaceutical use thereof. The novel carboxylic acid compound having a condensed ring and pharmacologically acceptable salt thereof of the present invention have superior GPIIb/IIIa antagonism in mammals inclusive of human; can be administered orally; have long life in blood and low toxicity; and show less side-effects. Accordingly, they are extremely useful for the prophylaxis and treatment of thrombotic diseases and other diseases

Chelating agents and method

A simple method for making EDTA, ED3A or DTPA analogs from amide derivatives of alpha amino acids is disclosed. These EDTA, ED3A or DTPA analogs are useful chelating agents, and preferably are useful as bifunctional chelating agents which may be attached to biological molecules and which form physiologically stable chelates with a variety of metal ions.